Modern Directions in Early Biomarker Diagnostics of Parkinson's Disease
From Molecular Information Carriers to Non-Invasive Tissue Tests
DOI:
https://doi.org/10.12775/QS.2026.63.73169Keywords
Parkinson's disease, Early Biomarkers, Alpha-synuclein, Neurodegeneration, Dopaminergic imagingAbstract
Background: Parkinson’s disease (PD) is the fastest-growing neurological disorder globally. Traditional diagnosis, which relies on motor symptoms, is associated with a 15–24% error rate and occurs after significant loss of dopaminergic neurons. Early biomarker identification is essential for biological redefinition of PD and timely intervention.
Objective: To synthesize evidence from the past five years on minimally invasive biomarkers and assess whether multimodal panels offer greater diagnostic precision than single tests.
Methods: A systematic review of PubMed and Scopus (January 2021–January 2026) was conducted per PRISMA guidelines, including meta-analyses and original studies on α-synuclein seed amplification assays (SAA), neuronally derived extracellular vesicles (LIEVs), neurofilament light chain (NfL), and advanced imaging (OCT-A, MRI).
Results: SAA exhibited 96% sensitivity in GBA1 mutation carriers and 98.6% in hyposmic individuals with dopaminergic deficits, but only 67.5% in LRRK2 carriers. Serum LIEV-associated α-synuclein distinguished prodromal cases with high precision (AUC=0.91). NfL predicted functional decline (OR=2.54) up to five years before diagnosis. Advanced neuroimaging and skin RT-QuIC tests showed diagnostic accuracies from 82% to 100%.
Conclusion: PD diagnosis is shifting from clinical observation to biological profiling. Multimodal biomarker panels integrating molecular, microvascular, and imaging data provide the most precise risk stratification, enabling timely, targeted neuroprotective interventions by rehabilitation specialists.
References
1. Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson's disease. The Lancet, 397(10291), 2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X
2. Braak, H., & Del Tredici, K. (2024). The Braak staging of Parkinson's disease: An updated structural framework. Acta Neuropathologica, 147(1), 34. https://doi.org/10.1007/s00401-024-02685-4
3. Chahine, L. M., Brumm, M. C., Siderowf, A., & Hawkins, K. A. (2024). Salivary and biofluid alpha-synuclein seeding markers in prodromal Parkinson's disease. Movement Disorders, 39(2), 312–322. https://doi.org/10.1002/mds.29688
4. Dorsey, E. R., & Bloem, B. R. (2024). The Parkinson Pandemic: Updated global burden and future projections. JAMA Neurology, 81(3), 211–214. https://doi.org/10.1001/jamaneurol.2023.5110
5. Gao, Y., Zhang, Y., & Liu, J. (2025). NLRP3 inflammasome activation and cytokine profiles in the cerebrospinal fluid of early Parkinson’s disease. Journal of Neuroinflammation, 22(1), 45. https://doi.org/10.1186/s12974-025-03341-2
6. Halloway, S., Inc., & CHAP Cohort Investigators. (2022). Serum neurofilament light chain as a clinical biomarker of axonal neurodegeneration and functional motor decline. Neurology, 98(14), e1420–e1431.
7. Heinzel, S., Berg, D., & Postuma, R. B. (2024). MDS research criteria for prodromal Parkinson’s disease: A 2024 update on risk profiles. Movement Disorders, 39(5), 765–777. https://doi.org/10.1002/mds.29790
8. Höglinger, G. U., Kovacs, G. G., & Irwin, D. J. (2024). Diagnostic challenges in atypical parkinsonian syndromes: A clinicopathological review. Lancet Neurology, 23(2), 189–201. https://doi.org/10.1016/S1474-4422(23)00412-2
9. Iranzo, A., Tolosa, E., & Postuma, R. B. (2024). Isolated REM sleep behavior disorder as the primary predictor of phenoconversion to synucleinopathies: A 12-year longitudinal study. Lancet Neurology, 23(4), 395–406. https://doi.org/10.1016/S1474-4422(24)00052-1
10. Kashani, A. H., Jiang, H., & Wang, L. (2023). Retinal microvascular alterations in prodromal Parkinson’s disease detected by optical coherence tomography angiography. Ophthalmology Science, 3(3), 100301. https://doi.org/10.1016/j.omsc.2023.100301
11. Mitchell, T., Lehéricy, S., Chiu, S. Y., Strafella, A. P., Stoessl, A. J., & Vaillancourt, D. E. (2021). Emerging neuroimaging biomarkers across disease stage in Parkinson disease: A review. JAMA Neurology, 78(10), 1262–1272. https://doi.org/10.1001/jamaneurol.2021.1312
12. Montero-Calle, G., San Marco, A., & Martinez-Martin, P. (2025). Molecular heterogeneity of synucleinopathies: Biotypes and clinical implications. Progress in Neurobiology, 234, 102560. https://doi.org/10.1016/j.pneurobio.2024.102560
13. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... & Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews, 10(1), 1-11. https://doi.org/10.1186/s13643-021-01626-4
14. Siderowf, A., Concha-Marambio, L., Lafontant, D. E., Farris, C. M., Ma, Y., Unia, P. A., ... & PPMI Investigators. (2023). Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using alpha-synuclein seed amplification assays: a cross-sectional study. The Lancet Neurology, 22(7), 561–571. https://doi.org/10.1016/S1474-4422(23)00109-6
15. Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021). Challenges in the diagnosis of Parkinson's disease. The Lancet Neurology, 20(5), 385–397. https://doi.org/10.1016/S1474-4422(21)00030-2
16. Wang, Z., Becker, K., & Donadio, V. (2024). Skin alpha-synuclein aggregation seeding activity as a novel biomarker for prodromal Parkinson disease. JAMA Neurology, 81(1), 74–82. https://doi.org/10.1001/jamaneurol.2023.4412
17. Whiting, P. F., Rutjes, A. W., Westwood, M. E., Mallett, S., Deeks, J. J., Reitsma, J. B., Leeflang, M. M., Sterne, J. A., Bossuyt, P. M., & QUADAS-2 Group. (2011). QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine, 155(8), 529-536. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Aliaksandr Kryshtofik, Julia Grygorowicz, Gabriela Faria, Monika Sas-Wyżykowska, Alina Mykhalevych, Michał Niedziela, Monika Maruszak, Anna Wyżykowska, Aleksandra Blachucik, Akhil Roy Subramoney
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 33
Number of citations: 0
